Asset Details
Do you wish to reserve the book?
Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro , in vivo , and clinical trials
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro , in vivo , and clinical trials
Do you wish to request the book?
Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro , in vivo , and clinical trials
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro , in vivo , and clinical trials
2021
Overview
Coronavirus disease 2019 (COVID-19) has spread worldwide and poses a threat to humanity. However, no specific therapy has been established for this disease yet. We conducted a systematic review to highlight therapeutic agents that might be effective in treating COVID-19.
We searched Medline, Medrxiv.org, and reference lists of relevant publications to identify articles of
,
, and clinical studies on treatments for severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and COVID-19 published in English until the last update on October 11, 2020.
We included 36 studies on SARS, 30 studies on MERS, and 10 meta-analyses on SARS and MERS in this study. Through 12,200 title and 830 full-text screenings for COVID-19, eight
studies, 46 randomized controlled trials (RCTs) on 6,886 patients, and 29 meta-analyses were obtained and investigated. There was no therapeutic agent that consistently resulted in positive outcomes across SARS, MERS, and COVID-19. Remdesivir showed a therapeutic effect for COVID-19 in two RCTs involving the largest number of total participants (n = 1,461). Other therapies that showed an effect in at least two RCTs for COVID-19 were sofosbuvir/daclatasvir (n = 114), colchicine (n = 140), IFN-β1b (n = 193), and convalescent plasma therapy (n = 126).
This review provides information to help establish treatment and research directions for COVID-19 based on currently available evidence. Further RCTs are required.
Publisher
Ivyspring International Publisher Pty Ltd,Ivyspring International Publisher
Subject
Adenosine Monophosphate - analogs & derivatives
/ Adenosine Monophosphate - therapeutic use
/ Alanine - analogs & derivatives
/ Animals
/ Antiviral Agents - therapeutic use
/ Cancer
/ Carbamates - therapeutic use
/ Coronavirus Infections - mortality
/ Coronavirus Infections - therapy
/ COVID-19
/ Drug Evaluation, Preclinical
/ Drug Therapy, Combination - methods
/ Humans
/ Imidazoles - therapeutic use
/ Immunization, Passive - methods
/ Middle East respiratory syndrome
/ Pyrrolidines - therapeutic use
/ Randomized Controlled Trials as Topic
/ Review
/ Severe Acute Respiratory Syndrome - mortality
/ Severe Acute Respiratory Syndrome - therapy
/ Sofosbuvir - therapeutic use
We currently cannot retrieve any items related to this title. Kindly check back at a later time.